Therapeutic effects of iNOS inhibition against vitiligo in an animal model


Submitted: 9 July 2019
Accepted: 10 July 2019
Published: 6 August 2019
Abstract Views: 1462
PDF: 691
HTML: 89
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Hamid Mansourpour Shahid Beheshti University of Medical Science, Tehran, Iran and AJA University of Medical Science, Tehran, Iran, Islamic Republic of.
  • Katayoun Ziari Department of Pathology, AJA University of Medical Science, Tehran, Iran, Islamic Republic of.
  • Sahar Kalantar Motamedi Shahid Beheshti University of Medical Science, Tehran, Iran, Islamic Republic of.
  • Amin Hassan Poor Tehran University of Medical Science, Tehran, Iran, Islamic Republic of.

Nitric oxide (NO) is involved in several biological processes, but its role in human melanogenesis and vitiligo need further studies. Previous studies revealed that exposure to UVA and UVB were capable of the inducing nitric oxide production in keratinocytes and melanocytes through the activation of constitutive nitric oxide synthase, whereas inducible nitric oxide synthase overexpression has been reported to play an important role in hyperpigmentary disorders. The aim of this study was to evaluate iNOS inhibitor aminoguanidine (AG) as a therapeutic agent in our mouse model of vitiligo. In this study, male C57BL/6J Ler-vit/vit mice were purchased to evaluate the effect of iNOS inhibitor (aminoguanidine) (50 and 100 mg/kg) and L-arginine (100 mg/kg) in a mouse model of vitiligo induced by monobenzone 40%. Moreover, we used phototherapy device to treat the mice with NBUVB as a gold standard.The findings revealed that monobenzone was capable of inducing depigmentation after 6 weeks. However, aminoguanidine in combination with monobenzone was decrease the effect of monobenzone, while L-arginine play a key role in promoting the effect of monobenzone (P<0.001). Based on the phototherapy, the efficacy of phototherapy significantly increased by adding L-arginine (P<0.05). Taken together, we suggest that iNOS inhibitor can be a novel treatment for the prevention and treatment of vitiligo by combination of NBUVB therapy, furthermore; NO agents like L-arginine could also increase the effectiveness of phototherapy. Taken together, this pilot study showed significant repigmentation of vitiligous lesions treated with iNOS inhibitor plus NBUVB therapy, where other aspect including expression of an inducible iNOS, NO and TNF levels remained to be evaluated in mice model.


Mansourpour, H., Ziari, K., Kalantar Motamedi, S., & Hassan Poor, A. (2019). Therapeutic effects of iNOS inhibition against vitiligo in an animal model. European Journal of Translational Myology, 29(3). https://doi.org/10.4081/ejtm.2019.8383

Downloads

Download data is not yet available.

Citations